Nektar Therapeutics (NKTR)

Market Cap	1.10B
Revenue (ttm)	62.60M
Net Income (ttm)	-120.74M
Shares Out	20.34M
EPS (ttm)	-7.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	646,424
Open	55.30
Previous Close	55.11
Day's Range	53.29 - 56.50
52-Week Range	6.48 - 66.92
Beta	1.28
Analysts	Strong Buy
Price Target	89.00 (+63.97%)
Earnings Date	Nov 6, 2025

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution pro...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 3, 1994
• Employees: 61
• Stock Exchange: NASDAQ
• Ticker Symbol: NKTR
• Website: https://www.nektar.com

Financial Performance

In 2024, Nektar Therapeutics's revenue was $98.43 million, an increase of 9.22% compared to the previous year's $90.12 million. Losses were -$118.96 million, -56.91% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for NKTR stock is "Strong Buy." The 12-month stock price target is $89.0, which is an increase of 63.97% from the latest price.

Price Target

$89.0

(63.97% upside)

Analyst Consensus: Strong Buy